Nona Biosciences extensional initiative for early clinical development and IITs

Announcement

Nona Biosciences, a leading biotechnology company thoroughly modernising the discovery pathway via innovative technology platforms have now extended its unified development and exploratory framework to contribute largely to Investigator-Initiated Trials (IITs) and early clinical development. This extension is an extension of the company’s potential to perform beyond exploring and IND-allowed activities to further bolster CMC toxicology, GMP and development manufacturing potential.

Via smart collaboration, internal technology innovations and platform acquisitions, the company will allow the worldwide biopharmaceutical companies to leverage the clinical trial initiation with strict quality and scientific standards. The company has not only granted a huge support to the IITs and early clinical development space but has also contributed to the vast healthcare sector.

Nona has proved its excellence via its tech-based solutions and promising platforms that have long supported and built confidence within the healthcare sector. Understanding the depth of science and the responsibility the biotech firm holds towards healthcare has made new ways for therapies to enter the sector.

Extended framework

The extended framework is built on Nona’s exclusive platforms involving Hu-mAtrlx™, Modalties-on-Demand™, NonaCarFx™, HBICE® and Harbour Mice®. Including the unified strong early clinical development and preclinical potential throughout CMC toxicology, clinical operation and development. By accelerating the renewed collaboration in advancing IITs and China, the company allows all the biopharmaceutical partners to make beneficial use of operational efficiency and developed infrastructure. This idea provides a speedy clinical trial initiation while simultaneously maintaining the high standards of regulatory compliance and development.

The company holds decades of fruitful experience in above 300 discovery programs and a rapid rise in the portfolio of clinically proven platforms. With this smooth and confident track record, the company will be continuing to modernise the next generation of biologic innovation to maintain its position as a technology-centric company. The company that encourages partners to progress from the valuable discovery via early clinical development with the help of our unified, promising, and high-performance platforms.

Chief Executive Officer of Nona Biosciences, Dr Di Hong, said, “Extending the company’s technology platforms and potential from antibody discovery to early clinic development marks an effortless progression of our smart vision. By merging our exclusive platforms with remarkable external partnerships and internal development initiative we are bolstering our potential value to allow smooth clinical translation without distracting our focus on forming scalable, classified technologies.”